| Product Code: ETC8843539 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Philippines continues to rely on imports for insulin biosimilars with key exporting countries in 2024 being Switzerland, India, South Korea, Germany, and USA. Despite the low concentration in market share, the negative CAGR of -17.36% from 2020 to 2024 indicates a declining trend. The steep decline in growth rate from 2023 to 2024 at -47.02% reflects challenges in the market. The market may see fluctuations in the coming years as it navigates through these dynamics.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Insulin Biosimilars Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Insulin Biosimilars Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Insulin Biosimilars Market - Industry Life Cycle |
3.4 Philippines Insulin Biosimilars Market - Porter's Five Forces |
3.5 Philippines Insulin Biosimilars Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Philippines Insulin Biosimilars Market Revenues & Volume Share, By Indicative, 2021 & 2031F |
3.7 Philippines Insulin Biosimilars Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Philippines Insulin Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Insulin Biosimilars Market Trends |
6 Philippines Insulin Biosimilars Market, By Types |
6.1 Philippines Insulin Biosimilars Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Insulin Biosimilars Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Philippines Insulin Biosimilars Market Revenues & Volume, By Rapid-acting biosimilar, 2021- 2031F |
6.1.4 Philippines Insulin Biosimilars Market Revenues & Volume, By Long-acting biosimilar, 2021- 2031F |
6.1.5 Philippines Insulin Biosimilars Market Revenues & Volume, By Premixed biosimilar, 2021- 2031F |
6.2 Philippines Insulin Biosimilars Market, By Indicative |
6.2.1 Overview and Analysis |
6.2.2 Philippines Insulin Biosimilars Market Revenues & Volume, By Type I Diabetes, 2021- 2031F |
6.2.3 Philippines Insulin Biosimilars Market Revenues & Volume, By Type II Diabetes, 2021- 2031F |
6.3 Philippines Insulin Biosimilars Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Philippines Insulin Biosimilars Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Philippines Insulin Biosimilars Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Philippines Insulin Biosimilars Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Insulin Biosimilars Market Import-Export Trade Statistics |
7.1 Philippines Insulin Biosimilars Market Export to Major Countries |
7.2 Philippines Insulin Biosimilars Market Imports from Major Countries |
8 Philippines Insulin Biosimilars Market Key Performance Indicators |
9 Philippines Insulin Biosimilars Market - Opportunity Assessment |
9.1 Philippines Insulin Biosimilars Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Philippines Insulin Biosimilars Market Opportunity Assessment, By Indicative, 2021 & 2031F |
9.3 Philippines Insulin Biosimilars Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Philippines Insulin Biosimilars Market - Competitive Landscape |
10.1 Philippines Insulin Biosimilars Market Revenue Share, By Companies, 2024 |
10.2 Philippines Insulin Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |